



ARSEUS
Driving superior care

Press Release

Regulated information

DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 30 December 2014 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 17 December 2014 to 29 December 2014, it acquired 59,539 treasury shares on Euronext Brussels.

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
17 December 2014	20,000	€ 31.4422	€ 31.35	€ 31.50	€ 628,844
18 December 2014	19,000	€ 31.9428	€ 31.55	€ 32.20	€ 606,913
19 December 2014	20,539	€ 32.7079	€ 32.45	€ 33.00	€ 671,788
22 December 2014	-	-	-	-	-
23 December 2014	-	-	-	-	-
24 December 2014	-	-	-	-	-
29 December 2014	-	-	-	-	-

The Extraordinary General Meeting held on 12 December 2014 approved the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus held 517,940 treasury shares. As a result of the acquisition of 59,539 treasury shares, Arseus now holds 577,479 treasury shares, representing 1.84% of the total number of shares outstanding.

Arseus will publish a weekly update every Monday provided that shares were bought back in the preceding week.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

¹ This press release was sent out by Arseus NV and Arseus BV.

For further information:

Marieke Palstra

Director Investor Relations

+31 88 33 11 213

marieke.palstra@arseus.com

Arseus profile

Arseus is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Arseus consists of two divisions: Fagron and HL Technology. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries.

Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals.

The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.